A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study
Authors: Chen Meiting , Li Lu , Xia Qing , Chen Xiaobing , Liao Zijun , Wang Chang , Shen Bo , Zhou Min , Zhang Qingyuan , Zhang Yanqiao , Qian Liting , Yuan Xianglin , Wang Zhehai , Xue Cong , An Xin , Liu Bin , Gu Kangsheng , Hou Mei , Wang Xiaojia , Wang Wei , Li Enxiao , Zhong Jincai , Cheng Jing , Shu Yongqian , Yang Nong , Wang Huaqing , Yang Runxiang , Liu Tianshu , Deng Ting , Ma Fei , Liao Wangjun , Qiu Wensheng , Chen Yu , Chen Xi , Zhang Mingzhi , Xu Ruilian , Li Xiaoling , Feng Jifeng , Ba Yi , Shi Yanxia 
Published: March 2024

Background

Studies on various thrombopoietic agents for cancer treatment–induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens.

Methods

In this retrospective, cross‐sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL‐11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO‐RA). The outcomes, compliance, and safety of different treatments were analyzed.

Results

Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL‐11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL‐11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy‐induced thrombocytopenia (CIT) than rhIL‐11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO‐RA alone than with rhTPO and rhIL‐11.

Conclusions

This survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL‐11, rhTPO, and TPO‐RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding.

Plain Language Summary

To provide an overview of the outcome of cancer treatment–induced thrombocytopenia in China, our cross‐sectional study analyzed 1437 cases treated with different thrombopoietic agents.

Most of the patients were treated with recombinant interleukin 11 (rhIL‐11) and recombinant thrombopoietin (rhTPO).

rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL‐11.